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Background: CT analyses of patients with severe aortic stenosis reveal that in the
majority of patients, the aortic annulus is not circular, but displays a certain degree of
eccentricity. All currently available percutaneous heart valve prostheses are circular in
shape. The aim of this study was to assess the performance of the transapical
JenaValve in an in vitro hydrodynamic test comparing circular and eccentric aortic
annulus geometry.
Methods: Based on CT data from 123 TAVI patients, a mean annulus eccentricity
(eccentricity¼short diameter/long diameter) of 0.84 was determined. Two models of
aortic roots with valve leaﬂets, one circular in shape and one displaying an eccentricity
of 0.84 were created based on the Reul model. The molds for the models were
3D-printed and cast from silicone. Valve hydrodynamics were evaluated in the CVE
pulse duplicator by analyzing high speed video recordings of leaﬂet motion, ﬂow and
pressure data. Measurements were performed 5l/min cardiac output, 80, 100 and 120
mmHg of mean aortic pressure and 120, 70 and 110 BPM, respectively. Experiments
were repeated in a cross-over design.
Results: The Analysis was performed with transapical JenaValve prostheses
implanted in a circular annulus (n¼3) or an annulus with 0.84 eccentricity (n¼3).
Hydrodynamic testing under both conditions showed good results without signiﬁcant
difference in performance. In the circular model the JenaValve showed an average
regurgitation volume (RV) of 3.49ccm0.12ccm corresponding 4.69%0.20% of the
total stroke volume (SV). An increase of RV to 3.57ccm1.61ccm corresponding
4.81%2.05% of the total SV was seen in the oval annulus, representing only a small
increase. Cross-over hydrodynamic testing showed similar results.
Conclusions: This is the ﬁrst experimental in vitro study demonstrating no signiﬁcant
difference in valve performance with regard to regurgitation volume for a commer-
cially available percutaneous valve whilst implanted in a circular and eccentric
annulus. This may be due to the slim and ﬂexible valve stent design, the use of
a native porcine root valve as opposed to single pericardial leaﬂets and the clipping
mechanism of the transapical JenaValve.
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Background: Transcatheter Aortic Valve Implantation (TAVI) has become
a reasonable approach for patients with severe symptomatic aortic stenosis (AS) and
high operative risk. This approach may be hampered by high occurrence of stroke
during and after the procedure. With the association of atrial ﬁbrillation (AF) and
CVA well documented, the objective of the present report was to evaluate the effect of
pre-procedural and new onset atrial ﬁbrillation (NOAF) on mortality and stroke
outcomes in patients undergoing TAVI.
Methods: We analyzed the data on 380 consecutive elective patients undergoing
TAVI between September 2008 and April 2013 in our interventional cardiology
department. Post-procedural AF was deﬁned as new onset AF occurring within 30
days of the index procedure. Follow up time was deﬁned as the time from the
procedure to an adverse outcome, either mortality of stroke.
Results: The mean follow-up time was 583 and 528 days for the outcome of CVA and
mortality respectively. For the total duration of follow-up, CVA and mortality
occurred in 19 (10%) and 68 (17.9%) patients respectively. At 30 days follow-up,
NOAF occurred in 31 (8.2%) cases and was not associated with higher rate of CVA
(0.4% vs. 3.2% of NOAF, p¼0.093, p¼0.36 in a multivariate analysis after adjust-
ment) or mortality (2.2% vs. 3.2%, p¼0.71). At 12-month follow-up no difference in
CVA rate or mortality was observed between groups. In contrast, patients with
background diagnosis of AF had an increased rate of CVA at 12 months follow-up
(1.5% vs. 6.8%, p¼0.007, p¼0.014 after adjustment for confounding risk factors for
CVA) and increased mortality (6.1% vs. 25.4%, p<0.001). The increased rate of CVA
and mortality was not driven by difference in baseline characteristics or risk factors for
CVA. CHA2DS2VASc score was similar in both groups (4.621.1 vs. 4.771.08,
p¼0.246).
Conclusions: The present data suggest that new onset atrial ﬁbrillation in the ﬁrst 30
days after TAVI does not increase signiﬁcantly stroke or mortality rate at 30 days and
1 year follow up. Importantly, prior diagnosis of AF signiﬁcantly increases the rate of
stroke and mortality, regardless of known risk factors and baseline characteristics.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-766
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Background: Transcatheter aortic valve replacement (TAVR) represent an "off label"
option to treat pure severe native aortic regurgitation (SAR) in patients unsuitable for
surgical aortic valve replacement due to their high surgical risk. We hereby report the
12 month follow-up of 12 cases of inoperable SAR treated in our Institute using
Medtronic CoreValve prosthesis.
Methods: Aortic valve sizing was assessed on 3 dimensional-CT scan and TEE
considering perimeter, area, major and minor orthogonal annular diameter. In all cases
an oversizing prosthesis (20%) with respect of annular perimeter was used. Pre-
dilation with balloon valvuloplasty was never performed. During valve deployment
a rapid (180 bpm) pacing was used in order to prevent valve ejection. Twelve patients
underwent TAVR with CoreValve prosthesis (mean age 83+4, 7; mean L-Euroscore
31%; male 60%).
Results: In 9 patients a procedural success has been reached using a single valve (n. 3
CoreValve 26 mm; n. 3 CoreValve 29 mm; n. 3 CoreValve 31 mm. Mean annulus size
24,7+ 2 mm) without major complications (no peri-procedural stroke or major
bleeding). A new permanent PM implantation was necessary in 3 pts. Post procedure
aortic regurgitation grade < 1 was present in 8 patients. In one case a second valve
deployment (CoreValve 29 mm in Core-Valve 31 mm) was necessary to reduce the
peri-leak severe aortic regurgitation obtaining a ﬁnal moderate grade of aortic
regurgitation. In 2 cases conversion to emergency open surgery and aortic valve
replacement was required due to residual severe aortic regurgitation despite a second
valve deployment (valve-in-valve). In these patients the large native annulus dimen-
sion (mean perimeter of 93+2 mm; mean area of 831+3 mm2) did not permit to use an
oversizing device and the CoreVale 31 mm was borderline. In all cases at 6- and
12-month follow up we observed an improved functional capacity (NYHA class I-II
post TAVR from NYHA IV pre TAVR was present in9 patients) and no death.
Conclusions: We hypotized that when an oversize prosthesis is used treating SAR by
TAVR acceptable results can be achieved. On the contrary very large native annulus
dimension should be considered a contraindication to TAVR in SAR
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Background: TAVI is an emerging therapy for aortic stenosis (AS) patients at high
surgical risk. The acute hemodynamic sequelae of this procedure and their clinical
relevance are yet unclear.
Methods: Consecutive patients who underwent TAVI in a single center were
prospectively monitored for BP response during 5 post-procedural days. Clinical
parameters, adverse events and medical treatment were recorded during hospitaliza-
tion, at 30 days and at 12 months after the procedure. Patients were divided according
to their post-procedural BP response into two groups: increased BP and stable BP.
Results: One hundred and ﬁve patients were analyzed. Overall, systolic BP increased
immediately after TAVI in the entire cohort by an average of 1531 mmHg. This rise
was sustained and led to intensiﬁcation of anti-hypertensive treatment in 53 patients
(51%), these patients were designated as the increased BP group. The increase in
systolic BP after TAVI was associated with an increase in stroke volume and cardiac
output and was not related to age, baseline cardiac function or procedural outcomes.
Patients with increased BP after TAVI had a signiﬁcantly better prognosis with less
adverse events in hospital (21% vs. 62%, p<0.01), after 30 days (30% vs. 71%,
p<0.01) and after 12 months (53% vs. 83%, p<0.01) as compared with patients with
stable BP.
Conclusions: After TAVI, a substantial number of patients have a signiﬁcant rise in
systolic BP necessitating long term treatment. This increase in BP is associated with
an increase in cardiac output and predicts a better clinical outcome.acts/POSTER/Aortic Valve Disease and Treatment B233
